139 related articles for article (PubMed ID: 28314697)
21. Inhibition of coagulation activation and inflammation by a novel Factor Xa inhibitor synthesized from the earthworm Eisenia andrei.
Joo SS; Won TJ; Kim JS; Yoo YM; Tak ES; Park SY; Park HY; Hwang KW; Park SC; Lee DI
Biol Pharm Bull; 2009 Feb; 32(2):253-8. PubMed ID: 19182385
[TBL] [Abstract][Full Text] [Related]
22. Factor Xa inhibits HMGB1-induced septic responses in human umbilical vein endothelial cells and in mice.
Lee W; Ku SK; Bae JS
Thromb Haemost; 2014 Oct; 112(4):757-69. PubMed ID: 25007770
[TBL] [Abstract][Full Text] [Related]
23. Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era.
Rühl H; Reda S; Müller J; Oldenburg J; Pötzsch B
Thromb Haemost; 2018 Feb; 118(2):381-387. PubMed ID: 29378360
[TBL] [Abstract][Full Text] [Related]
24. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
[TBL] [Abstract][Full Text] [Related]
25. Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors.
Terakami T; Nagaya S; Hayashi K; Furusho H; Fujino N; Kato T; Asakura H; Morishita E
J Atheroscler Thromb; 2022 Jul; 29(7):1059-1068. PubMed ID: 34334529
[TBL] [Abstract][Full Text] [Related]
26. Rivaroxaban Inhibits Angiotensin II-Induced Activation in Cultured Mouse Cardiac Fibroblasts Through the Modulation of NF-κB Pathway.
Hashikata T; Yamaoka-Tojo M; Namba S; Kitasato L; Kameda R; Murakami M; Niwano H; Shimohama T; Tojo T; Ako J
Int Heart J; 2015; 56(5):544-50. PubMed ID: 26370374
[TBL] [Abstract][Full Text] [Related]
27. FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms.
Moñux G; Zamorano-León JJ; Marqués P; Sopeña B; García-García JM; Laich de Koller G; Calvo-Rico B; García-Fernandez MA; Serrano J; López-Farré A
Br J Clin Pharmacol; 2017 Dec; 83(12):2661-2670. PubMed ID: 28735510
[TBL] [Abstract][Full Text] [Related]
28. Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban.
Jourdi G; Siguret V; Martin AC; Golmard JL; Godier A; Samama CM; Gaussem P; Gouin-Thibault I; Le Bonniec B
Thromb Haemost; 2015 Jul; 114(1):78-86. PubMed ID: 25761505
[TBL] [Abstract][Full Text] [Related]
29. A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver.
Yamaguchi Y; Okabe K; Liang J; Matsumura F; Ohshiro H; Ishihara K; Matsuda T; Takeya M; Kuratsu JI; Mori K; Yamada S; Ogawa M
Dig Dis Sci; 1999 Dec; 44(12):2568-76. PubMed ID: 10630515
[TBL] [Abstract][Full Text] [Related]
30. The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction.
Bode MF; Auriemma AC; Grover SP; Hisada Y; Rennie A; Bode WD; Vora R; Subramaniam S; Cooley B; Andrade-Gordon P; Antoniak S; Mackman N
Thromb Res; 2018 Jul; 167():128-134. PubMed ID: 29843086
[TBL] [Abstract][Full Text] [Related]
31. Independent anti-angiogenic capacities of coagulation factors X and Xa.
Lange S; Gonzalez I; Pinto MP; Arce M; Valenzuela R; Aranda E; Elliot M; Alvarez M; Henriquez S; Velasquez EV; Orge F; Oliva B; Gonzalez P; Villalon M; Cautivo KM; Kalergis AM; Pereira K; Mendoza C; Saez C; Kato S; Cuello MA; Parborell F; Irusta G; Palma V; Allende ML; Owen GI
J Cell Physiol; 2014 Nov; 229(11):1673-80. PubMed ID: 24615682
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin-(1-7) Attenuates Angiotensin II-Induced ICAM-1, VCAM-1, and MCP-1 Expression via the MAS Receptor Through Suppression of P38 and NF-κB Pathways in HUVECs.
Liang B; Wang X; Zhang N; Yang H; Bai R; Liu M; Bian Y; Xiao C; Yang Z
Cell Physiol Biochem; 2015; 35(6):2472-82. PubMed ID: 25967876
[TBL] [Abstract][Full Text] [Related]
33. Coagulation cascade activation causes CC chemokine receptor-2 gene expression and mononuclear cell activation in hemodialysis patients.
Pertosa G; Simone S; Soccio M; Marrone D; Gesualdo L; Schena FP; Grandaliano G
J Am Soc Nephrol; 2005 Aug; 16(8):2477-86. PubMed ID: 15976001
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of activated factor X; a new pathway in ameliorating carbon tetrachloride-induced liver fibrosis in rats.
Mahmoud NI; Messiha BAS; Abo-Saif AA; Abdel-Bakky MS
J Biochem Mol Toxicol; 2019 May; 33(5):e22287. PubMed ID: 30719803
[TBL] [Abstract][Full Text] [Related]
35. Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction.
Liu J; Nishida M; Inui H; Chang J; Zhu Y; Kanno K; Matsuda H; Sairyo M; Okada T; Nakaoka H; Ohama T; Masuda D; Koseki M; Yamashita S; Sakata Y
J Atheroscler Thromb; 2019 Oct; 26(10):915-930. PubMed ID: 30867376
[TBL] [Abstract][Full Text] [Related]
36. Lipopolysaccharide pretreatment increases protease-activated receptor-2 expression and monocyte chemoattractant protein-1 secretion in vascular endothelial cells.
Chao HH; Chen PY; Hao WR; Chiang WP; Cheng TH; Loh SH; Leung YM; Liu JC; Chen JJ; Sung LC
J Biomed Sci; 2017 Nov; 24(1):85. PubMed ID: 29141644
[TBL] [Abstract][Full Text] [Related]
37. Factor Xa releases matrix metalloproteinase-2 (MMP-2) from human vascular smooth muscle cells and stimulates the conversion of pro-MMP-2 to MMP-2: role of MMP-2 in factor Xa-induced DNA synthesis and matrix invasion.
Rauch BH; Bretschneider E; Braun M; Schrör K
Circ Res; 2002 May; 90(10):1122-7. PubMed ID: 12039803
[TBL] [Abstract][Full Text] [Related]
38. TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1.
Shinozawa E; Nakayama M; Imura Y
Front Pharmacol; 2018; 9():1431. PubMed ID: 30568593
[TBL] [Abstract][Full Text] [Related]
39. Edoxaban's contribution to key endothelial cell functions.
Almengló C; Mosquera-Garrote N; González-Peteiro M; González-Juanatey JR; Álvarez E
Biochem Pharmacol; 2020 Aug; 178():114063. PubMed ID: 32492447
[TBL] [Abstract][Full Text] [Related]
40. Puerarin prevents vascular endothelial injury through suppression of NF-κB activation in LPS-challenged human umbilical vein endothelial cells.
Deng HF; Wang S; Li L; Zhou Q; Guo WB; Wang XL; Liu MD; Liu K; Xiao XZ
Biomed Pharmacother; 2018 Aug; 104():261-267. PubMed ID: 29775893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
